article thumbnail

The Benefits of Digital Transformation in Generic Drug Development

Drug Patent Watch

Revolutionizing Generic Drug Development: The Power of Digital Transformation As the pharmaceutical industry continues to evolve, one thing is clear: digital transformation is no longer a luxury, but a necessity. So, what does this mean for the future of generic drug development? Share your thoughts in the comments below!

article thumbnail

Recorded Webinar: Streamlining Collaborations and Drug Development using CDD Vault

Collaborative Drug

Streamlining Collaborations and Drug Development using CDD Vault and ELN

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Importance of Pharmacovigilance in Generic Drug Development

Drug Patent Watch

The Unseen Heroes of Generic Drug Development: Pharmacovigilance As a generic drug developer, you're no stranger to the challenges of bringing affordable medications to market. But have you ever stopped to think about the unsung heroes of generic drug development?

article thumbnail

Real-World Evidence in Clinical Drug Development

Quanticate

Real-world evidence (RWE) is changing clinical drug development, bridging the gap between controlled clinical trial environments and the complexities of everyday patient experiences.

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.

article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

Haemoglobin A1c (HbA1c) is a validated surrogate endpoint for the reduction of microvascular complications associated with diabetes mellitus; reduced HIV-RNA levels serve as an endpoint for HIV disease control; and a reduction in low-density lipoprotein (LDL) cholesterol is used as an endpoint indicating lower likelihood of cardiovascular events.

article thumbnail

Q&A: How to jump-start new psychiatric and neurological drug development

Broad Institute

They wrote that a deeper understanding of the molecular mechanisms driving these disorders will improve diagnosis, enhance patient stratification in clinical trials, and lead to better therapeutics.